Name:
Type:
PI
Grant Award Details
Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Grant Type:
Grant Number:
DISC2-12124
Project Objective:
- To enable the development of a combination therapeutic candidate composed of an HA hydrogel loaded with heparin nanoparticles, VEGF clusters and hESC-derived human islet-like organoids (HILO) to treat Type I Diabetes.
Investigator:
Disease Focus:
Diabetes
Metabolic Disorders
Type 1 diabetes
Human Stem Cell Use:
Embryonic Stem Cell
Award Value:
$250,000
Status:
Pre-Active
Grant Application Details
Application Title:
- Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Public Abstract:
Research Objective
Functional human islet like organoids differentiated from human pluripotent stem cells.
Impact
Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients.
Major Proposed Activities
- Fabrication and characterization of the injectable immunomodulating and pro-angiogenic material components: HA hydrogel, heparin nanoparticles and VEGF clusters.
- Generation of human islet like organoids from pluripotent stem cells for subcutaneous transplantation
- Subcutaneous HILOs transplantation in pre-vasculature site in NOD-SCID mice.
- Subcutaneous PD-L1 expressing HILOs transplantation in pre-vasculature site in Hu-PBMC-NSG mice
Statement of Benefit to California:
The cell and technology products proposed by this diabetes therapeutic study will significantly improve future diabetes treatments in the State of California, particularly benefiting vulnerable populations, such as Hispanics, African-Americans, men, older populations, homeless individuals, and those of lower socioeconomic status. Additionally, this proposed research may create greater research employment opportunities in the South Bay, a region within Los Angeles County.
